BioVentures Investors

BioVentures Investors is a private equity firm based in Marlborough, Massachusetts, specializing in venture capital investments within the life sciences and healthcare sectors. Established in 1998 by Marc Goldberg, the firm focuses on opportunities in medical devices, diagnostics, and commercial technology. BioVentures Investors aims to support innovative companies that are poised to advance healthcare solutions and improve patient outcomes.

Barnes, Jeffrey T.

General Partner

Peter Feinstein

Venture Partner

John Osborn

Venture Partner and Principal

36 past transactions

BRAINBox Solutions

Series A in 2020
BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems.

Sonomotion

Series B in 2019
Sonomotion is a medical device manufacturing company that specializes in providing medical solutions for kidney stones disease. The company's stone repositioning solution is currently in clinical trials and its second-generation stone breaking technology is in development. Sonomotion was founded in 2014 and headquartered in South San Francisco, California.

Kanova

Series A in 2018
Kanova is a biopharmaceutical company that focuses on developing therapeutic antibodies and innovative combination therapies in immuno-oncology and autoimmune diseases.

Endotronix

Series D in 2018
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

Unified Information Devices

Venture Round in 2018
UID’s Identification Solutions optimize the identification of animals, vials, cages using implantable transponders, readers, labels and Software.

CoNextions Medical

Venture Round in 2017
CoNextions Medical manufactures tendon repair surgical healthcare equipment. It offers CoNextionsTR, stainless steel, and ultra-high molecular weight polyethylene implant that is designed for the surgically address tendon injuries. Despite advancements in biomaterials, operative techniques, and postoperative rehabilitation protocols, complications following suture repair of tendons are still common. Its flagship product, CoNextionsTR is an alternative to traditional suture repair techniques. This stainless steel and ultra-high molecular weight polyethylene implant are designed for the approximation of tendons 1-4mm in thickness and 3-7mm in width. CoNextions Medical is a medical technology company dedicated to dramatically improve patient outcomes and the economics of tendon repair worldwide.

POC Medical Systems

Series A in 2017
Testing that is performed near or at the site of patient care with the result leading to possible change in the course of care of the patient. Testing that is performed outside a central laboratory environment, generally nearer to, or at the site of the patient. Also referred to as “near-patient” testing, or “point-of-need testing

Endotronix

Series C in 2016
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

Nano-Micro Technology

Series A in 2015
Nano-Micro Technology manufactures monodisperse particles in a range of sizes and serves a variety of industries and applications. They provide solutions such as configurable resin development and purification process development. The company's contact modes are phone and physical address.

InSeal Medical

Venture Round in 2012
The InSeal technology is based on an internal biodegradable membrane which seals the puncture.

Cylene Pharmaceuticals

Series D in 2010
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Hydrocision

Venture Round in 2010
HydroCision develops, manufactures, and markets fluidjet based surgical tools for minimally invasive spine surgery requirements. Its products include SpineJet HydroSurgery System that is used to ablate, cut, and remove targeted tissue for spinal procedures, Spinejet, water-based technology solutions for minimally invasive spine surgery requirements, SpineJet HydroDiscectomy Systems, which are used to remove tissue without the risk of thermal energy for minimally invasive discectomy procedures, and AlloJet, systems to prepare bone allografts. The company also provides customer care services. HydroCision, Inc. was formerly known as Surgijet Corporation and changed its name to HydroCision, Inc. in November 1996. The company was founded in 1994 and is headquartered in North Billerica, Massachusetts.

Claros Diagnostics

Series B in 2009
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.

Hydra Biosciences

Series D in 2009
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Hydra Biosciences

Series C in 2008
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Verax Biomedical

Series E in 2007
Verax Biomedical was founded upon the singular vision of detecting bacterial contamination in cells and tissues intended for transfusion and transplantation. Recognizing that bacteria pose a unique infectious challenge in these life-giving tissues, they realized that novel approaches to detection were called for. While these cellular materials are routinely tested for viral contaminants, bacteria have posed a long-standing and heretofore poorly addressed challenge. Unlike viruses, bacteria can replicate outside of a living host, meaning they can grow in these cellular matrices during storage prior to transfusion or transplantation. This results in the unique dilemma of an infectious contaminant that can grow from unmeasurably low levels at the time of collection to massive levels at the time of transfusion or transplantation, posing a serious and often fatal risk to their recipient.

Cardiosolutions

Series A in 2007
Cardiosolutions was founded in 2006 by STD Med, Inc., a leading medical device manufacturer, in order to develop less invasive alternatives to open surgical procedures addressing the mitral valve of the heart.

Verax Biomedical

Venture Round in 2007
Verax Biomedical was founded upon the singular vision of detecting bacterial contamination in cells and tissues intended for transfusion and transplantation. Recognizing that bacteria pose a unique infectious challenge in these life-giving tissues, they realized that novel approaches to detection were called for. While these cellular materials are routinely tested for viral contaminants, bacteria have posed a long-standing and heretofore poorly addressed challenge. Unlike viruses, bacteria can replicate outside of a living host, meaning they can grow in these cellular matrices during storage prior to transfusion or transplantation. This results in the unique dilemma of an infectious contaminant that can grow from unmeasurably low levels at the time of collection to massive levels at the time of transfusion or transplantation, posing a serious and often fatal risk to their recipient.

Sciona

Venture Round in 2007
Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Spirus Medical

Series B in 2007
Spirus Medical is a developer of advanced care medical devices for the gastrointestinal and cardiovascular markets. The company’s product portfolio includes the Endo-Ease Discovery and Dexterity Steerable Introducer.

Cylene Pharmaceuticals

Series C in 2007
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Claros Diagnostics

Series A in 2007
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.

Sciona

Series C in 2006
Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Verax Biomedical

Series B in 2005
Verax Biomedical was founded upon the singular vision of detecting bacterial contamination in cells and tissues intended for transfusion and transplantation. Recognizing that bacteria pose a unique infectious challenge in these life-giving tissues, they realized that novel approaches to detection were called for. While these cellular materials are routinely tested for viral contaminants, bacteria have posed a long-standing and heretofore poorly addressed challenge. Unlike viruses, bacteria can replicate outside of a living host, meaning they can grow in these cellular matrices during storage prior to transfusion or transplantation. This results in the unique dilemma of an infectious contaminant that can grow from unmeasurably low levels at the time of collection to massive levels at the time of transfusion or transplantation, posing a serious and often fatal risk to their recipient.

Cylene Pharmaceuticals

Series B in 2005
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Enanta Pharmaceuticals

Venture Round in 2004
Enanta Pharmaceuticals, Inc., a research and development company, engages in the discovery, development, and promotion of small molecule drugs in the areas of anti-infective. It develops protease, NS5A, polymerase, and cyclophilin-based inhibitors for the treatment of hepatitis C virus (HCV). The company also develops ABT-450/r, an oral protease inhibitor for the treatment of hepatitis C (HCV) infection. In addition, it develops Bicyclolides, a macrolide antibiotic, which overcomes bacterial resistance; and EDP-420, a bicyclolide antibiotic for the treatment of community-acquired pneumonia. The company's antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA. The company has strategic alliances with Abbott Laboratories; and Shionogi & Co., LTD. Enanta Pharmaceuticals, Inc. was formerly known as NovirX, Inc. and changed its name to Enanta Pharmaceuticals, Inc. in May 1999. The company was founded in 1998 and is based in Watertown, Massachusetts.

Enanta Pharmaceuticals

Venture Round in 2004
Enanta Pharmaceuticals, Inc., a research and development company, engages in the discovery, development, and promotion of small molecule drugs in the areas of anti-infective. It develops protease, NS5A, polymerase, and cyclophilin-based inhibitors for the treatment of hepatitis C virus (HCV). The company also develops ABT-450/r, an oral protease inhibitor for the treatment of hepatitis C (HCV) infection. In addition, it develops Bicyclolides, a macrolide antibiotic, which overcomes bacterial resistance; and EDP-420, a bicyclolide antibiotic for the treatment of community-acquired pneumonia. The company's antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA. The company has strategic alliances with Abbott Laboratories; and Shionogi & Co., LTD. Enanta Pharmaceuticals, Inc. was formerly known as NovirX, Inc. and changed its name to Enanta Pharmaceuticals, Inc. in May 1999. The company was founded in 1998 and is based in Watertown, Massachusetts.

Hydra Biosciences

Series B in 2004
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Angiolink Corporation

Series B in 2003
Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.

Verax Biomedical

Series A in 2003
Verax Biomedical was founded upon the singular vision of detecting bacterial contamination in cells and tissues intended for transfusion and transplantation. Recognizing that bacteria pose a unique infectious challenge in these life-giving tissues, they realized that novel approaches to detection were called for. While these cellular materials are routinely tested for viral contaminants, bacteria have posed a long-standing and heretofore poorly addressed challenge. Unlike viruses, bacteria can replicate outside of a living host, meaning they can grow in these cellular matrices during storage prior to transfusion or transplantation. This results in the unique dilemma of an infectious contaminant that can grow from unmeasurably low levels at the time of collection to massive levels at the time of transfusion or transplantation, posing a serious and often fatal risk to their recipient.

Ardais Corporation

Series C in 2003
Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.

Pintex Pharmaceuticals

Series B in 2002
Pintex Pharmaceuticals, Inc. is a private pharmaceuticals company headquartered in Watertown, MA., that is engaged in the discovery and development of structure-based cancer therapeutics. In particular, the focus of Pintex's research is on the phosphate specific proline isomerase Pin1 enzyme and its key role in cancer. Pintex was founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard University, Dr. Walter Gilbert, a Nobel Prize winning professor at Harvard University and Dr. Janusz Sowadski, co-founder of Kinetix Pharmaceuticals, Inc., and a past recipient of the US Supercomputing Award for structure-based kinase inhibitor designs. Pintex was created in order to harness the many years of research and discovery performed and patented by researchers at the Salk Institute for Biological Studies and Harvard University.

Angiolink Corporation

Series A in 2002
Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.

Verax Biomedical

Series A in 2002
Verax Biomedical was founded upon the singular vision of detecting bacterial contamination in cells and tissues intended for transfusion and transplantation. Recognizing that bacteria pose a unique infectious challenge in these life-giving tissues, they realized that novel approaches to detection were called for. While these cellular materials are routinely tested for viral contaminants, bacteria have posed a long-standing and heretofore poorly addressed challenge. Unlike viruses, bacteria can replicate outside of a living host, meaning they can grow in these cellular matrices during storage prior to transfusion or transplantation. This results in the unique dilemma of an infectious contaminant that can grow from unmeasurably low levels at the time of collection to massive levels at the time of transfusion or transplantation, posing a serious and often fatal risk to their recipient.

Pintex Pharmaceuticals

Series A in 2002
Pintex Pharmaceuticals, Inc. is a private pharmaceuticals company headquartered in Watertown, MA., that is engaged in the discovery and development of structure-based cancer therapeutics. In particular, the focus of Pintex's research is on the phosphate specific proline isomerase Pin1 enzyme and its key role in cancer. Pintex was founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard University, Dr. Walter Gilbert, a Nobel Prize winning professor at Harvard University and Dr. Janusz Sowadski, co-founder of Kinetix Pharmaceuticals, Inc., and a past recipient of the US Supercomputing Award for structure-based kinase inhibitor designs. Pintex was created in order to harness the many years of research and discovery performed and patented by researchers at the Salk Institute for Biological Studies and Harvard University.

Phase Forward

Venture Round in 2000
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's technology and global services are designed to enable life sciences companies to automate and integrate the management of their entire clinical development process, from study initiation and FDA submission through post-marketing studies. Until its acquisition by Oracle in April 2010, Phase Forward was a publicly held company. Its corporate headquarters were in Waltham, Massachusetts, international headquarters in Maidenhead, UK, and its regional offices in the U.S., Japan, France and Australia. Phase Forward was founded in 1997 by Paul Bleicher, M.D, Ph.D., who had experienced firsthand the complexities involved in developing and conducting paper-based trials, in particular, capturing, managing, and growing volumes of data. Dr. Bleicher's vision was to develop technology that would enable organizations to make the shift from paper-based methods to Internet-enabled solutions. His pioneering efforts have contributed significantly to Phase Forward's evolution from initial concept to its current industry-leading position. Spearheading the evolution of electronic data capture (EDC) with its industry-leading InForm solution, Phase Forward transformed the way clinical data are collected, analyzed and managed. With the acquisition of Lincoln Technologies' innovative safety management solutions, Phase Forward took steps to provide the end-to-end solutions customers need to track and monitor product efficacy and safety, while building their trials more efficiently and cost-effectively.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.